bronchopulmonary dysplasia

Early Selective Ibuprofen for Patent Ductus Arteriosus Fails to Improve Outcomes in Extremely Preterm Infants: Insights from the Baby-OSCAR Trial

By MedXY 02/20/2026

The Baby-OSCAR trial demonstrates that early selective treatment of large patent ductus arteriosus with ibuprofen in extremely preterm infants does not significantly reduce death or bronchopulmonary dysplasia, nor does it improve neurodevelopmental outcomes at two years.

news Pediatrics Respiratory

Pathophysiological Divergence in Preterm Infants: Early Lung Aeration and Gas Exchange as Predictors of Moderate-to-Severe Bronchopulmonary Dysplasia

By MedXY 02/08/2026

A multicentre prospective study reveals that infants developing moderate-to-severe BPD exhibit significant lung aeration and gas exchange deficits as early as day 10, with a critical pathophysiological peak at 26 days of life, regardless of the BPD definition used.

news Pediatrics Respiratory

Evaluating Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: Insights from the BiB Randomized Clinical Trial

By MedXY 10/10/2025

The BiB trial showed that adding budesonide to surfactant did not reduce bronchopulmonary dysplasia or death in extremely preterm infants but was associated with increased hyperglycemia risk.